ApyraMed exploits as active principle, apyrase alone or in different dosage/combination (including live biotherapeutics) to enhance endogenous secretory IgA in pathophysiological conditions.
Technology
MV BioTherapeutics has developed modified microorganisms and recombinant proteins with unique potentials in a wide range of therapeutic indications
ApyraVax exploits apyrase in different vectors and drug combinations to elicit specific mucosal responses conferring protection against infection by pathogens.